This is a Reach announcement and the information contained is not considered to be material or to have a significant impact on management's expectations of the Company's performance. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.
26 February 2024
MicroSalt plc
("MicroSalt" or the "Company")
Notice of investor webinar
MicroSalt plc, (AIM: SALT) a company commercialising a patented technology to produce full-flavour, low-sodium salt for food manufacturers and consumers, is pleased to announce that Rick Guiney (CEO) and Konrad Dabrowski (CFO), will be presenting at the London South East/focusIR investor webinar on Tuesday 27 February at 7pm (UK local time).
Following the presentation, attendees will have the opportunity to ask questions. If you would like to attend, you can register for free using the link below:
For more information, please visit www.microsaltinc.co, follow on X @microSaltPLC or contact:
MicroSalt plc | Via Flagstaff |
Rick Guiney, CEO | |
| |
Flagstaff PR (Financial IR/FPR) | +44 (0)20 7129 1474 |
Tim Thompson / Alison Allfrey / Anna Probert microsalt@flagstaffcomms.com | |
Notes to Editors
MicroSalt® produces a patented full-flavour, low-sodium salt for food manufacturers and consumers.
MicroSalt is a major potential disruptor in the food market, thanks to its micron sized particles which deliver the same sense of saltiness to a wide range of foods but with approximately 50% less sodium. Excess sodium consumption is a significant contributor to cardiovascular disease and MicroSalt's solution meets the rising demand for healthier alternatives to traditional salt. The WHO has set a target for reducing global sodium intake by 30% by 2025, which it estimates will save 7 million lives by 2030.
Each year, cardiovascular disease costs the UK £19 billion - if the average salt intake was reduced by one gram per day, it has been estimated that 4,147 lives and £288 million would be saved each year in the UK. As a nation, the UK consumes 183 million kilograms of salt each year, and 70% of the typical person's sodium intake is hidden in processed foods.
Operational since 2018, MicroSalt uses a patent-protected technology which helps create high barriers to entry within the reduced-sodium salt market.
The Directors believe that MicroSalt is well positioned to capture growth in the low sodium market, which is expected to grow exponentially, and that there is also scope to enter the larger salt market.
ENDS
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.